已使用胰島素的第2型糖尿病病人合併Thiazolidinedione治療在其臨床表現和副作用的探討

Evaluation of the clinical manifestation and side effects of type 2 diabetics used insulin treated with thiazolidinedione

郭姿岑(Tzu-Tsen Kuo)

指導教授 ： 黃耀斌

共同指導教授 ： 蘇聖棋(Sheng-Chi Su)

高雄醫學大學/藥學院/藥學研究所碩士在職專班/碩士(2011年)

摘要

本研究目的藉由在已使用胰島素並加入thiazolidinedione (TZD)治療第2型糖尿病的收案病人探討其臨床表現Glycated hemoglobin (HbA1c)和胰島素減少的劑量及副作用(體重增加和增加水腫發生)。因TZD會增加胰島素的敏感性，降低胰島素阻抗，所以TZD加胰島素可以降低胰島素劑量、降低HbA1c和增加體重、水腫的發生。研究中根據世界衛生組織的標準，收案病人均已被診斷為第2型糖尿病，且使用胰島素治療至少三個月(有或沒有合併使用口服降血糖藥物)，雖然持續使用同類胰島素但血糖並未獲得良好的控制。根據收案標準和排除條件，篩選至最後有38人符合進入本研究分析，這38人確定使用TZD之前有使用胰島素至少三個月和使用TZD之後一直持續使用胰島素。最主要影響效力的變項(primary efficacy)是HbA1c和胰島素劑量，其次影響效力的第二變項(secondary efficacy)包括體重變化和水腫情形。38位收案病人的分析探討，依四項評估指標進行分析：(1) HbA1c改變；(2)胰島素劑量減少；(3)病人體重變化；(4)病人水腫變化。研究結果顯示HbA1c的改變、病人的體重及水腫變化均有統計上的意義。病人在收案前使用SG/Glinides、metformin、AGI口服降血糖藥物和胰島素治療或單獨胰島素治療，血糖沒有得到適當的控制，收案後把TZD加入在已使用胰島素治療第2型糖尿病的病人，病人血糖有獲得較好控制和有減低胰島素劑量的趨勢，顯示TZD加胰島素比單獨使用胰島素可將血糖控制在較好的情況，也可以使已經在使用胰島素的病人減低胰島素劑量。當發生水腫時，通常可藉由減少TZD劑量和或加利尿劑來控制。總之，雖然要注意TZD加胰島素可能產生的副作用(水腫和體重增加)，但是當病人有血糖控制不好時，TZD合併胰島素應該是可以被考慮使用的。
關鍵字: 胰島素、thiazolidinedione、第2型糖尿病、糖化血色素

關鍵字

胰島素 ； thiazolidinedione ； 第2型糖尿病 ； 糖化血色素

並列摘要

The aim of this study is conferring the clinical manifestations and side effects in type 2 diabetics who treated by insulin with thiazolidinedione (TZD). TZD would raise the insulin sensitivity and reduce the insulin impedance, so TZD with insulin could decrease the insulin dosage, HbAlc and the morbidity of weight and dropsy gain. The patients who included this study according to the standard of WHO were type 2 diabetics treated with insulin for 3 months at least. The same kind of insulin was used in this period and the blood sugar couldn’t get control well. According to the included and excluded criteria, there were 38 patients fitted this analysis. They used insulin for 3 month at least before treating TZD, and kept taking insulin after treating TZD. In this study, the primary efficacy was to estimate HbAlc and record insulin dosage, the secondary efficacy included the change of weight and the situation of dropsy. The evaluation of this study showed that the mean value on 38 patients according to 4 appraisal targets: (1) the change of HbAlc; (2) decreasing the insulin dosage; (3) the weight change of the patients; (4) the dropsy change of the patients. After included this case, the patients were combined with TZD in type 2 diabetics who treated insulin. We found that the patients’ blood sugar were controlled well and seem decreased insulin dosage. It was shown that TZD with insulin could control blood sugar better than treating insulin only, and also could decrease insulin dosage in the patients who were using insulin. When dropsy occurred, we could suggest decreasing TZD dosage or adding the diuretic. Briefly, we might have to pay attention the side effect such as dropsy or weight gain occurred when we use TZD with insulin. And then the patient’s blood sugar out of control, it could be considered to treat by TZD with insulin.

Key words: insulin, thiazolidinedione, type 2 diabetics, Glycated hemoglobin (HbA1c)

並列關鍵字

insulin ； thiazolidinedione ； type 2 diabetics ； Glycated hemoglobin (HbA1c)

參考文獻

Aguilar-Bryan L, Bryan J, Nakazaki M. Of mice and men: K(ATP) channels and insulin secretion. Recent Prog Horm Res. 2001; 56: 47-68.

American Diabetes Association.Standards of Medical Care in Diabetes(Position statement) Diabetes Care. 2010; 33,S13.

Ammann RW, Muellhaupt B. The natural history of pain in alcoholic chronic pancreatitis. Gastroenterology. 1999; 116: 1132-1140.

Asnani S, Kunhiraman B, Jawa A, Akers D, Lumpkin D, Fonseca V. Pioglitazone restores endothelial function in patients with type 2 diabetes treated with insulin. Metab Syndr Relat Disord. 2006; 4(3): 179–184.

Bailey CJ. Hypoglycaemic, antihyperglycaemic and antidiabetic drugs. Diabet Med. 1992 Jun; 9(5): 482-3.